Factor Xa Inhibitors Market Size to Attain USD 41.52 Billion by 2034

Factor Xa Inhibitors Market Size, Segments and Companies

The global factor Xa inhibitors market was estimated at US$ 22.1 billion in 2023 and is projected to grow to US$ 41.52 billion by 2034, rising at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2034. The growing prevalence of various heart-related health issues is driving the market.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

Inhibitors of factor Xa (FXa) are the most recent class of anticoagulants. They attach to FXa and prevent prothrombin from cleaving into thrombin, which stops the coagulation cascade. Because of their quick onset and brief half-lives, they offer the benefit of requiring less "bridging" close to surgery. Currently, several oral and injectable direct factor Xa inhibitors are in clinical development.

Factor Xa Inhibitors Market Trends

• In November 2022, Since January 2022, more than 24 million prescriptions for anticoagulant drugs have been written, preventing an estimated 17,000 strokes and 4,000 deaths, and over 460,000 more individuals have started taking these drugs.
• The patent on Janssen Pharms' Xarelto, one of the best-selling anticoagulant medications, expired in August 2024. Patients with nonvalvular atrial fibrillation can lower their risk of stroke and systemic embolism by using Xarelto (rivaroxaban), an oral direct factor Xa inhibitor.

Market Opportunity: DOACs are the Future

DOACs are the future of the factor Xa inhibitors market. Pharmacological research over the last ten years has produced novel direct oral anticoagulants (DOACs) that target molecules that can inhibit certain and individual coagulative cascade pathways. The goal of developing new DOACs is to provide an effectiveness that is at least as high as that of VKAs. There is a lot of optimism for the future since clinical research is being done to broaden the list of indications for DOACs, and experience is still expanding outside of the trial environment.

Market Challenge: Side Effects of Factor Xa Inhibitors

The factor Xa inhibitors market faces challenges in growth due to various side effects associated with the drugs. Bleeding, usually from the nose, gastrointestinal tract (GI), or genitourinary system, is one of the possible side effects. Direct factor Xa inhibitors have a decreased risk of brain bleeding but a higher risk of gastrointestinal bleeding when compared to the risk of bleeding with warfarin usage. Additional adverse effects might include nausea, lightheadedness, anemia, or elevated liver enzyme levels in the blood.

Regional Insights

North America dominated the factor Xa inhibitors market in 2023.

Many reasons contribute to North America's supremacy, including the region's sophisticated healthcare system, government assistance, rising pharmaceutical investments, and the innovation and financial commitments of major industry participants. Canada and the United States are the two main nations that support the market's expansion.

Atrial fibrillation is a common cause of stroke, and the prevalence of stroke is increasing in the U.S., which is promoting the growth of the factor Xa inhibitors market. For instance, In 2022, stroke was the cause of one in six fatalities (17.5%) from cardiovascular disease in the U.S. Between 2021 and 2022, the stroke death rate dropped from 41.1 per 100,000 to 39.5 per 100,000. In the U.S., a stroke occurs every 40 seconds or so. A stroke claims a life in this nation every 3 minutes and 11 seconds. In America, almost 795,000 people have a stroke each year. There are around 610,000 new or first strokes.

Asia Pacific is expected to grow at the fastest rate during the forecast period.

Asia Pacific is the biggest and most populated region, and it has advantages, including a broad consumer base and a large labor pool. Due to technological advancements, healthcare spending, and the participation of international market players, the factor Xa inhibitors market is growing quickly in the region. Another important factor contributing to the growth is the increasing prevalence of CVDs in the region. Among the countries that largely encourage the market's growth are China and India.

India records one stroke death every four minutes, making stroke the second leading cause of mortality in the nation, according to neurologist M V Padma Srivastava. Speaking at an event, Srivastava claimed that India has the highest rate of stroke, with a 68.6% incidence, a 70.9% stroke mortality rate, and a 77.7% loss of disability-adjusted life years (DALYs).

For instance

• In January 2024, the science-driven biopharmaceutical business AstraZeneca Pharma India Ltd. declared that the Central Drugs Standard Control Organization (CDSCO) in India has given its permission for the import and sale of Andexanet Alfa. This innovative medication treats bleeding that is resistant or life-threatening and is linked to the usage of Factor Xa (FXa) inhibitors.

Segmental Insights

By type, the oral drugs segment held the largest share of the factor Xa inhibitors market in 2023. Along with ease and compliance, the medication's pharmacokinetic and pharmacodynamic properties also affect how the drug is administered. Therefore, it is crucial to understand the characteristics of the various routes and associated tactics. Oral administration is one of the most widely used, practical, and cost-effective ways to deliver medication. The small intestine is usually where most drug absorption takes place, and the amount of drug absorbed via the intestinal epithelium influences the bioavailability of the treatment.

By application, the atrial fibrillation segment held a significant share of the factor Xa inhibitors market in 2023. It is atrial fibrillation that causes strokes most frequently. Patients with atrial fibrillation who get anticoagulant treatment have a lower risk of stroke and other embolic consequences. Projected studies indicate that by 2050, there will be 15.9 million Americans with AF, and by 2060, there will be 17.9 million in Europe.

Recent Developments

• In February 2024, Roche announced the introduction of three new coagulation tests in countries that accept the CE mark for the oral Factor Xa inhibitors rivaroxaban, edoxaban, and apixaban.
• In December 2023, in an ongoing Phase I clinical study, Sirnaomics Ltd. and its subsidiaries reported that Cohort 1 of STP122G, a new anticoagulant strategy that targets Factor XI, was successfully completed.

Top Companies in the Factor Xa Inhibitors Market

• Pfizer
• Hansoh Pharma
• Daiichi Sankyo
• Bayer
• Shanghai Huilun Pharmaceutical
• Viatris
• Dr. Reddy's Laboratories
• GlaxoSmithKline
• Janssen Pharmaceuticals
• Eugia Pharma
• Chia Tai Tianqing Pharmaceutical
• Accord Healthcare
• Bristol Myers Squibb
• Apotex, Zydus
• Lupin
• Nanjing King-Friend Biochemical Pharmaceutical
• HEC Pharma
• Jiangsu Hengrui Pharmaceuticals
• Cspc Ouyi Pharmaceutical
• Qilu Pharmaceutical
• BrightGene
• Zhejiang Hisun Pharmaceutical
• Kelun Pharmaceutical

Segments Covered in the Report

By Type

• Oral Drugs
• Injections

By Application

• Atrial Fibrillation
• Pulmonary Embolism
• Deep Vein Thrombosis
• Other

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait